Senate cuts follow-on biologics tax cut
Executive Summary
The Senate version of recently introduced follow-on biologics legislation, the "Access to Life-Saving Medicine Act" (1S 4016), unlike the House bill, does not include a tax credit for studies performed to demonstrate interchangeability. According to the office of Sen. Hillary Clinton (D-N.Y.), the provision was omitted to avoid a joint referral to the Finance Committee in addition to the Health Committee. Renewal of the Prescription Drug User Fee Act will be under the Health Committee, and Clinton's office believes PDUFA could be a vehicle for follow-on biologics legislation...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.